Tirzep (Tirzepatide INN) the "1st Twincretin of Bangladesh" available in 2.5 mg, 5 mg, and 7.5 mg pre-filled syringes.
It highlights Tirzepatide's unique dual action through GLP-1 and GIP receptors, both approved by the FDA and EMA. This dual mechanism helps to manage diabetes and obesity by improving metabolic outcomes.
The diagram explains how Tirzepatide affects different body systems:
CNS: Reduces caloric intake and maintains energy balance.
Heart: Increases heart rate but doesn't necessarily translate to a significant increase in blood pressure or an increased risk of hypertension.
Pancreas: Enhances insulin secretion while reducing glucagon.
Gut: Slows gastric emptying and reduces chylomicron production.
Adipose Tissue: Facilitates glucose and triglyceride uptake, promoting storage.
Kidneys: Causes transient sodium excretion.
Bones: Supports bone remodelling related to meals.
Liver: Boosts glucose uptake and glycogen production while reducing hepatic glucose output.
